In the News

413 News Items found
MSK physician scientist Piro Lito, MD, PhD
Q&A
Learn about insights that could lead to a new class of drugs against cancers caused by RAS gene mutations.
A female nurse talks with a female patient, who is sitting in an exam chair
Feature
Advances in diagnosis and treatment, especially those made over the past ten years, have played a significant role in the decline in cancer deaths. Learn about those advances — and what to expect in the next ten years.
Enlarged microscopic image of blue-green immune cells surrounding one blue cancer cell.
Q&A
Some of the first clinical trials testing immunotherapy for the treatment of sarcoma are now under way at MSK. Here’s a snapshot of where the research stands.
MSK researcher in a lab
MSK Research Highlights, August 24, 2023
New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.
msk patient christopher jeter and his wife connie
Meet Christopher Jeter, who was diagnosed nearly 10 years ago with lung cancer. He was successfully treated at Memorial Sloan Kettering and now is being closely monitored by experts in MSK's Adult Survivorship Program.
Allison Betof Warner uses a pipette in the lab
Using patients’ own immune systems to fight cancer has been one of the most exciting advances in cancer treatment over the past decade. Now, a new immunotherapy could take this approach to the next level.
Piro Lito, Bob Li, and Neal Rosen in the lab
In the Clinic
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
David Hyman and Robin Gillespie
Finding
Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.
A scientist holding a tube in a lab
Take a look back at some of the biggest science stories from this past year.
Detail of an MSK scientist working in a lab
MSK Research Highlights, October 31, 2023
New MSK research identifies a promising immunotherapy target for acute myeloid leukemia; decodes genetic differences in tumors from patients with African ancestry; and finds a virtual mind-body fitness program reduced hospitalizations for those in active cancer treatment. A clinical trial led by MSK also resulted in the approval of a new combination therapy for non-small cell lung cancer.